bioMerieux SA · EURONEXT:BIM

bioMerieux SA — H1 2024 Earnings Presentation

27 slides from bioMerieux SA's earnings presentation, September 2024

  1. Slide 1: H1 2024 Results & Outlook 2024

    H1 2024 RESULTS & OUTLOOK 2024 September 2024 PIONEERING DIAGNOSTICS 2024 half year results presentation / B I O M É R I E U X

  2. Slide 2: Agenda

    AGENDA 1. GO.28 Strategic Plan Pierre BOULUD 2. H1 2024 Business Highlights Pierre BOULUD 3. H1 2024 Financial Performance Guillaume BOUHOURS 4. 2024 Business outlook Pierre BOULUD

  3. Slide 3: Disclaimer

    Disclaimer This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieu

  4. Slide 4: GO.28 Strategic Plan

    Pierre BOULUD, CEO GO.28 Strategic Plan Reminder & updates 2024 half year results presentation / B I O M É R I E U X

  5. Slide 5: GO.28 strategic plan pillars

    The GO.28 strategic plan is driven by 4 pillars 4 GROWTH ENGINES MAXIMIZE VALUE OF Average annual organic sales growth to 2028 vs 2024 INSTALLED BASE BIOFIRE® Non-RP +10%* +7%* BIOFIRE® RP ~ Flat* for Growth average Sales INDUSTRIAL APP. +7/9%* Growth (24/28) +6/8% * IMMUNOASSAYS ~ Flat* MICROBIOLOG

  6. Slide 6: GO.28 ambition: profitable and sustainable growth 2024/2028

    GO.28 ambition: delivering a profitable and sustainable growth over the period 2024 / 2028 REVENUE CEBIT(1) MARGIN GROWTH at Constant Exchange Rate 20% AT LEAST +7% 16.6 %%+340 +10% bps annual organic Annual organic cEBIT growth at CAGR (2024 / 2028) CER1 2023 2023 2028e 2028E / Capex: Maintain R&D

  7. Slide 7: GO.28 is now live and execution has started

    GO.28 is now live and execution has started Innovation to support growth +10% sales growth Q2 2024 product launches in H1 2024 vs +7% SPOTFIRE® Respiratory / Sore Throat Panel 15-plex & 5-plex (Mini) for Growth annual guidance VITEK® REVEALTM Instrument & Gram Negative Blood culture COGS improvement

  8. Slide 8: Responsible: on track to reach 2024 ambitions

    Responsible : on track to reach 2024 ambitions PLANET HEALTH GHG absolute emissions reduction vs 2019 (Scope 1&2) % increase in patient results -14% -50% supporting AMS vs 2019 As of June 2024 2030 TARGET +18% Solar panels on sites / Green power purchase agreements / Renewable Energy Certificates As

  9. Slide 9: H1 2024 Business highlights

    Pierre BOULUD, CEO H1 2024 Business highlights 2024 half year results presentation / B I O M É R I E U X

  10. Slide 10: H1 2024 Key highlights

    H1 2024 Key highlights SALES CONTRIBUTIVE FREE EBIT CASHFLOW €1,902m €50m €306m +9.9%* 16.1% of sales Net Debt / EBITDA X0.3 ▪ Strong sales dynamic driven by the GO.28 four growth engines (BIOFIRE non-Respiratory Panels, Spotfire, Microbiology and Industrial Applications) up +11.4% ▪ CEBIT margin up

  11. Slide 11: BIOFIRE non respiratory panels: value driving strong growth

    GROWTH ENGINE #1 BIOFIRE® non respiratory panels: value driving strong growth H1 Sales: €272m Evol. +19%* GO.28 target: +10%** ▪ Expansion of non-respiratory panels through cross-selling • 77% of customers using at least 2 panels (up +2 pp vs Dec. 2023) • 50% of customers using at least 3 panels (up

  12. Slide 12: SPOTFIRE: on track to reach €80m sales target in 2024

    GROWTH ENGINE #2 SPOTFIRE®: on track to reach €80m sales target in 2024 ▪ Most comprehensive, flexible and fastest Point of Care respiratory offer H1 Sales: €33m • Fast: 15 minutes Time To Result Evol: n.a. • Easy to use: CLIA Waived 2028 target: €450m • Approval of Respiratory Sore throat • Full &

  13. Slide 13: Microbiology: leveraging our leading position

    GROWTH ENGINE #3 MICROBIOLOGY: leveraging our leading position H1 Sales: €638m Evol. +9%* GO.28 target: +6/8%** ▪ BacT & Vitek reagents: mid-teens sales growth ▪ Growth driven by volumes expansion and price increases (+4% on reagents) and ▪ Large adoption of VITEK® MS PRIME: 550+ instruments*** ▪ VI

  14. Slide 14: Industrial Applications: growing in highly attractive segments

    GROWTH ENGINE #4 INDUSTRIAL APPLICATIONS: growing in highly attractive segments H1 Sales: €296m Evol. +7%* GO.28 target: +7 / 9%** ▪ Growth driven mainly by the food segment, especially the molecular biology franchise ▪ Food & Healthcare reagents sales up +11% ▪ Price increases : > +6% supporting gr

  15. Slide 15: Maximizing value of installed base for BIOFIRE respiratory panels and Immunoassays

    Maximizing the value of the existing installed base for BIOFIRE® respiratory panels and Immunoassays H1 Sales: €405m ▪ Leveraging the installed base BIOFIRE ▪ Double digit growth thanks to sustained epidemiology Respiratory Panels Evol. +14%* ▪ Limited price erosion (<1%) GO.28 target: flat** ▪ VIDA

  16. Slide 16: H1 2024 Financial performance

    Guillaume BOUHOURS, CFO H1 2024 Financial performance 2024 half year results presentation / B I O M É R I E U X

  17. Slide 17: H1 2024 Sales by range

    H1 2024 SALES BY RANGE A strong and balanced performance SPOTFIRE €33m ▪ 1,450 instruments installed MICROBIOLOGY +9% at the end of June 2024 ▪ Very strong performance led by automated ▪ Live in 16 countries. ID/AST and Blood Culture ▪ Volumes and prices increases MOLECULAR Non-RP +19% Remarkable pe

  18. Slide 18: H1 2024 sales by geography

    H1 2024 sales by geography EMEA €616m 32% of sales +8.8% AMERICAS ASPAC €971m €315m 51% of sales 17% of sales +12.9% +3.9% 2024 half year results presentation / B I O M É R I E U X 18

  19. Slide 19: HY 2024 P&L: CEBIT up 20% like-for-like

    HY 2024 P&L: CEBIT up 20% like-for-like HY % HY % % % In €m sales sales Change Change LFL(1) 2024 2023 Net sales 1,902 1,770 + 7.4% + 9.9% Gross profit 1,063 55.9% 999 56.4% + 6.4% + 11.9% SG&A -536 - 28.2% -502 -28.4% + 6.8% + 9.4% R&D -241 - 12.7% -227 -12.8% + 6.3% + 6.4% CEBIT (2) 306 16.1% 291

  20. Slide 20: H1 2024 P&L: CEBIT to EPS

    H1 2024 P&L: CEBIT to EPS H1 % HY % % change In €m sales sales 2024 2023 as reported CEBIT 306 16.1% 291 16.5% +5.0% Amortization of acquired intangible assets & related -18 -84 expenses Operating income before non-recurring items 288 15.2% 208 11.7% +38.7% Net financial expense -5 +0.5 Income tax (

  21. Slide 21: Cash flow statement: up +€49m vs H1 2023

    CASH FLOW STATEMENT: up +€49m vs H1 2023 • Inventories (-€84m) driven by inventory build- Millions € June 2024 June 2023 up for new instruments launches and to support the steady demand in Biofire® reagents and the EBITDA (1) 424 394 coming winter season • Receivables (+€35m): good cash collection i

  22. Slide 22: HY 2024: -€44m FX negative impact on CEBIT

    HY 2024: -€44m FX negative impact on CEBIT ▪ -€21m from hyperinflation currencies (ARS, TRY…) ▪ Increased prices to compensate for inflation and currency devaluation o Positive impact on top line organic growth & on CEBIT organic growth o Negative currency effect* on CEBIT o Neutral net impact on re

  23. Slide 23: 2024 outlook

    Pierre BOULUD, CEO 2024 outlook 2024 half year results presentation / B I O M É R I E U X

  24. Slide 24: 2024 Outlook

    2024 Outlook UPDATED GUIDANCE INITIAL GUIDANCE (March 2024) +8% to +10% SALES Organic +6% to +8% Better on Biofire® RP, Biofire® non-RP, Organic Microbiology +12 to +17% At least!!! +10% cEBIT Organic > 50 bps margin improvement Organic Approx -€70m FX negative impact Approx -€50m FX negative impact

  25. Slide 25: Conclusion: GO.28 on track and starts delivering

    is on track and starts delivering ▪ H1 24 growth engines organic sales up +11.4% ▪ H1 24 Gross Margin up +100 bps (organic) vs H1 2023 ▪ H1 24 GHG emissions: -14% vs H1 2023 ▪ On track to pursue the execution of the plan • ~75% of the GO.Simple 50+ initiatives have started • High employees’ engageme

  26. Slide 26: bioMérieux – Pioneering Diagnostics

    BIOMERIEUX PIONEERING DIAGNOSTICS

  27. Slide 27: CSR roadmap – on track to reach the targets

    CSR ROADMAP – ON TRACK TO REACH THE TARGETS All data as of June 2024, except for Philantropy & referenced antibiotics (Dec 23 data) PLANET EMPLOYEES HEALTHCARE EXTENDED HEALTH ECOSYSTEM COMPANY Collaboration projects +18% -14% Lost Day Incident Rate with patient associations 1.6% vs. 2021 of net inc

bioMérieux — H1 2024 Earnings Presentation on 6ix